User profiles for Jebrane Bouaoud
Jebrane BouaoudMD, PhD; Sorbonne Université, Unit of Maxillo-Facial Surgery, Pitié-Salpêtrière Hospital … Verified email at aphp.fr Cited by 460 |
[HTML][HTML] Precision medicine approaches to overcome resistance to therapy in head and neck cancers
S Ortiz-Cuaran, J Bouaoud, A Karabajakian… - Frontiers in …, 2021 - frontiersin.org
Head and neck squamous cell carcinoma (HNSCC) is the sixth most incident cancer
worldwide. More than half of HNSCC patients experience locoregional or distant relapse to …
worldwide. More than half of HNSCC patients experience locoregional or distant relapse to …
[HTML][HTML] Unmet needs and perspectives in oral cancer prevention
Simple Summary Oral cavity is the most common site of head and neck cancer which is ranked
as the eighth most common cancer worldwide. Oral cancer treatment is often associated …
as the eighth most common cancer worldwide. Oral cancer treatment is often associated …
Biomarkers of radioresistance in head and neck squamous cell carcinomas
Purpose Head and neck squamous cell carcinoma (HNSCC) is a major cause of morbidity
and mortality. Although HNSCC is mainly caused by tobacco and alcohol consumption, …
and mortality. Although HNSCC is mainly caused by tobacco and alcohol consumption, …
[HTML][HTML] Immunologically active phenotype by gene expression profiling is associated with clinical benefit from PD-1/PD-L1 inhibitors in real-world head and neck and …
…, M Boussageon, L Michon, J Bouaoud… - European Journal of …, 2022 - Elsevier
Introduction Identification of tumours harbouring an overall active immune phenotype may
help for selecting patients with advanced head and neck squamous cell carcinomas (HNSCC) …
help for selecting patients with advanced head and neck squamous cell carcinomas (HNSCC) …
[HTML][HTML] MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer
…, AB Shnerb, S Mathukkada, J Bouaoud… - … for ImmunoTherapy of …, 2022 - ncbi.nlm.nih.gov
Original research: MEK1/2 inhibition transiently alters the tumor immune microenvironment to
enhance immunotherapy efficacy against head and neck cancer - PMC Back to Top Skip to …
enhance immunotherapy efficacy against head and neck cancer - PMC Back to Top Skip to …
Early changes in the immune microenvironment of oral potentially malignant disorders reveal an unexpected association of M2 macrophages with oral cancer free …
Understanding the dynamics of the immune microenvironment is critical to the development
of immuno-based strategies for the prevention of oral potentially malignant disorders …
of immuno-based strategies for the prevention of oral potentially malignant disorders …
[HTML][HTML] Longitudinal assessment of PD-L1 expression and gene expression profiles in patients with head and neck cancer reveals temporal heterogeneity
Background Programmed death-ligand 1 (PD-L1) is the most validated predictive biomarker
used for the treatment of head and neck squamous cell carcinoma (HNSCC) with immune …
used for the treatment of head and neck squamous cell carcinoma (HNSCC) with immune …
DIVA, a 3D virtual reality platform, improves undergraduate craniofacial trauma education
J Bouaoud, M El Beheiry, E Jablon, T Schouman… - Journal of Stomatology …, 2021 - Elsevier
Craniofacial fractures management is challenging to teach due to the complex anatomy of
the head, even when using three-dimensional CT-scan images. DIVA is a software allowing …
the head, even when using three-dimensional CT-scan images. DIVA is a software allowing …
[PDF][PDF] CDYL2 epigenetically regulates MIR124 to control NF-κB/STAT3-dependent breast cancer cell plasticity
…, B Gibert, M Ouzounova, J Bouaoud… - Iscience, 2020 - cell.com
Epigenetic deregulation of gene transcription is central to cancer cell plasticity and malignant
progression but remains poorly understood. We found that the uncharacterized epigenetic …
progression but remains poorly understood. We found that the uncharacterized epigenetic …
[HTML][HTML] Datasets for gene expression profiles of head and neck squamous cell carcinoma and lung cancer treated or not by PD1/PD-L1 inhibitors
…, S Ortiz-Cuaran, M Boussageon, L Michon, J Bouaoud… - Data in Brief, 2022 - Elsevier
Identification of tumors harboring an overall active immune phenotype may help for selecting
patients with advanced head and neck squamous cell carcinomas (HNSCC) and non-small …
patients with advanced head and neck squamous cell carcinomas (HNSCC) and non-small …